Literature DB >> 2818255

Reliability of clinical nurse specialists in the staging of dementia.

M M McCulla1, M Coats, N Van Fleet, J Duchek, E Grant, J C Morris.   

Abstract

We studied the reliability of master's-prepared clinical nurse specialists for the identification and staging of dementia, using videotapes of physician assessments of both healthy older persons and those with senile dementia of the Alzheimer type. The Washington University (St Louis, Mo) Clinical Dementia Rating system was the staging instrument. The results from three nurses, each reviewing 25 videotaped assessments, indicate that agreement is high between clinical nurse specialists and physicians for the presence and severity of dementia (kappa = .75). This study suggests that clinical nurse specialists can use the Clinical Dementia Rating scale effectively, and thus reliably identify and stage dementia.

Entities:  

Mesh:

Year:  1989        PMID: 2818255     DOI: 10.1001/archneur.1989.00520470070029

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  26 in total

1.  Mortality in nursing home residents without cognitive impairment and its relation to self-reported health-related quality of life, sociodemographic factors, illness variables and cancer diagnosis: a 5-year follow-up study.

Authors:  Jorunn Drageset; Geir Egil Eide; Anette Hylen Ranhoff
Journal:  Qual Life Res       Date:  2012-03-02       Impact factor: 4.147

Review 2.  Utility of the clinical dementia rating in Asian populations.

Authors:  Wee Shiong Lim; Mei Sian Chong; Suresh Sahadevan
Journal:  Clin Med Res       Date:  2007-03

3.  The "portable" CDR: translating the clinical dementia rating interview into a PDA format.

Authors:  James E Galvin; Thomas M Meuser; Mary A Coats; Donald A Bakal; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

4.  Sample size requirements for training to a kappa agreement criterion on clinical dementia ratings.

Authors:  Rochelle E Tractenberg; Futoshi Yumoto; Shelia Jin; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

5.  FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology.

Authors:  Qinwen Mao; Xiaojing Zheng; Tamar Gefen; Emily Rogalski; Callen L Spencer; Rosa Rademakers; Angela J Fought; Missia Kohler; Sandra Weintraub; Haibin Xia; Marek-Marsel Mesulam; Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2019-09-01       Impact factor: 3.685

6.  Diagnosis and staging of mild cognitive impairment, using a modification of the clinical dementia rating scale: the mCDR.

Authors:  Ranjan Duara; David A Loewenstein; Maria T Greig-Custo; Ashok Raj; Warren Barker; Elizabeth Potter; Elizabeth Schofield; Brent Small; John Schinka; Yougui Wu; Huntington Potter
Journal:  Int J Geriatr Psychiatry       Date:  2010-03       Impact factor: 3.485

7.  Reliability of monitoring the clinical dementia rating in multicenter clinical trials.

Authors:  Kimberly A Schafer; Rochelle E Tractenberg; Mary Sano; Joan A Mackell; Ronald G Thomas; Anthony Gamst; Leon J Thal; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

8.  Autobiographical memory task in assessing dementia.

Authors:  Denise Maue Dreyfus; Catherine M Roe; John C Morris
Journal:  Arch Neurol       Date:  2010-07

9.  Role of family history for Alzheimer biomarker abnormalities in the adult children study.

Authors:  Chengjie Xiong; Catherine M Roe; Virginia Buckles; Anne Fagan; David Holtzman; David Balota; Janet Duchek; Martha Storandt; Mark Mintun; Elizabeth Grant; Abraham Z Snyder; Denise Head; Tammie L S Benzinger; Joseph Mettenburg; John Csernansky; John C Morris
Journal:  Arch Neurol       Date:  2011-10

10.  Methods to improve the detection of mild cognitive impairment.

Authors:  William R Shankle; A Kimball Romney; Junko Hara; Dennis Fortier; Malcolm B Dick; James M Chen; Timothy Chan; Xijiang Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.